% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Desert:302883,
      author       = {R. Desert and F. Gianonne and A. Saviano and Y. Hoshida and
                      M. Heikenwälder$^*$ and P. Nahon and T. F. Baumert},
      title        = {{I}mproving immunotherapy for the treatment of
                      hepatocellular carcinoma: learning from patients and
                      preclinical models.},
      journal      = {Gut and liver},
      volume       = {2},
      number       = {1},
      issn         = {1976-2283},
      address      = {Seoul},
      publisher    = {Ed. Office of Gut and Liver},
      reportid     = {DKFZ-2025-01423},
      pages        = {8},
      year         = {2025},
      abstract     = {Hepatocellular carcinoma (HCC), the third cause of
                      cancer-related deaths worldwide, continues to present
                      significant therapeutic challenges. Despite significant
                      therapeutic advancement in the last decade, the efficacy of
                      systemic treatments for patients with advanced HCC remains
                      unsatisfactory. While the clinical introduction of immune
                      checkpoint inhibitors has improved response rates and
                      overall survival, their clinical success remains still
                      limited. Here we provide a comprehensive review of current
                      and emerging strategies aimed at enhancing the efficacy of
                      immunotherapy for the treatment of HCC. Both clinical
                      studies conducted in patients as well as studies in
                      preclinical models have markedly advanced our understanding
                      of resistance as well as uncovered novel approaches to
                      overcome resistance. Recent progress is paving the way for
                      improved efficacy and safety of novel approaches that will
                      improve the dismal prognosis of patients with advanced HCC.},
      subtyp        = {Review Article},
      keywords     = {Humans / Carcinoma, Hepatocellular: therapy / Carcinoma,
                      Hepatocellular: immunology / Liver Neoplasms: therapy /
                      Liver Neoplasms: immunology / Immunotherapy: methods /
                      Immune Checkpoint Inhibitors: therapeutic use / Animals /
                      Disease Models, Animal / Immune Checkpoint Inhibitors (NLM
                      Chemicals)},
      cin          = {D440},
      ddc          = {610},
      cid          = {I:(DE-He78)D440-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40626281},
      pmc          = {pmc:PMC7617876},
      doi          = {10.1038/s44355-025-00018-y},
      url          = {https://inrepo02.dkfz.de/record/302883},
}